Investors support saliva metabolomics testing

Founded in 2024 by Kevin Hof and Christopher Wall, Maven Health is specialized in Saliva-based metabolomics, a scientific approach that involves the comprehensive analysis of metabolites present in saliva to gain insights into biological processes, health, and disease states. With their new test kit 'Metabolic Insights test', Maven Health provides a more comprehensive and convenient method for assessing individuals’ health and areas for improvement. Offered as a lifestyle tool for metabolic health optimization, the technology enables non-invasive, saliva-based profiling that translates complex data into personalized insights through proprietary methods and IP. Positioned within the preventive health market, the solution enables the flexible integration into preventive health, wellness programs and personalized coaching. The platform further supports multiple applications across both academic research and industry, enabling broader translational value beyond individual health optimization.  

The Metabolic Insights test is available on the market already and are used by a growing network of practitioners (clinics and nutrition professionals) in Switzerland.  A new practitioner booking platform has recently been launched to support onboarding and client consultations. In parallel, Maven Health is expanding its commercial footprint with its distributor in the Netherlands, with further negotiations in Europe underway. This strengthens the strategy to expand throughout Europe in the coming years. 

With the closing of its strategic seed round, the Zurich-based startup is now set for further commercial expansion. The round includes new capital from three existing business angel investors, and formalizes the conversion of earlier commitments made through convertible loan agreements from Founderful Campus Fund, S2S Ventures, a strategic NMR laboratory partner and several angel investors. “We’re seeing considerable excitement from nutritionists, integrative health professionals, academics and commercial partners who want rigorous, science-backed tools that are practical in everyday care in the preventive health setting,” said Kevin Hof, co-CEO of Maven Health. “The capital raised helps us grow distribution, expand our practitioner network and continue improving the clients’ customer experience.” 

This investment round also formalizes the participation of two student venture capital funds, Founderful Campus Fund and S2S Ventures, who backed Maven Health at the pre-seed stage. Their involvement underscores the momentum behind a new wave of science-driven startups emerging from Switzerland’s academic ecosystem. 

“We invested in Maven Health because of its scientific depth, interesting IP, commercial clarity and the team's ability to build fast with a lean team,” said one of the Business Angels, an ex-entrepreneur himself. “They are defining the next category of real-world preventive health tools and delivering on it.”